Stock research
AGIO Agios Pharmaceuticals, Inc.
Healthcare • Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings...…
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
3M change
+8.93%
Range high
$44.01
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in AGIO?
Price
Showing 3M history. Source: FMP historical price full.
- Prev Close
- $32.75
- Day High
- $33.34
- Day Low
- $29.97
- 52w High
- $46.00
- 52w Low
- $22.24
- Volume
- 2,099,928
- Avg Volume
- Beta
- 0.54
* TTM/most recent where available
Company
- Ticker
- AGIO
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Brian Goff
- Employees
- 540
- Website
- www.agios.com
Key Metrics
- Market Cap
- 1.79B
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).